Document Detail

Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review.
MedLine Citation:
PMID:  17227788     Owner:  NLM     Status:  MEDLINE    
AIMS: To assess the efficacy and safety of adjunctive antiarrhythmic drug therapy for preventing implantable cardioverter defibrillator (ICD) therapies. METHODS AND RESULTS: We conducted a systematic literature search to identify all randomized, controlled trials assessing the efficacy of adjunctive antiarrhythmic drug therapy. Trial data were reviewed and extracted independently by two investigators in an unblinded, standardized manner. Eight trials including a total of 1889 patients were analysed. There was heterogeneity in the type of antiarrhythmic used in the treatment arm (amiodarone, sotalol, azimilide, and dofetilide) as well as in the control group (five trials compared with placebo and three trials compared with beta-blocker). The main outcome, risk of shock therapy, was reduced when comparing amiodarone plus beta-blocker with beta-blocker alone (HR 0.27; 95% CI 0.14-0.52) and when comparing sotalol with placebo (HR 0.55; 95% CI 0.4-0.78). The effect was not conclusive when comparing sotalol with other beta-blocker (HR 0.61; 95% CI 0.37-1) and azimilide or dofetilide with placebo (HR 0.78; 95% CI 0.58-1.04 and HR 0.67; 95% CI 0.43-1.04, respectively). Although there were some benefits for secondary outcomes in all antiarrhythmics, the magnitude of the benefit was higher with amiodarone. CONCLUSION: Amiodarone is the most effective treatment to reduce ICD shock therapies. The benefit of other antiarrhythmics is limited to secondary outcomes.
Ignacio Ferreira-González; Laura Dos-Subirá; Gordon H Guyatt
Related Documents :
24200228 - The relationship between axis i psychopathology and quality of life in adults with mild...
18162018 - Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a q...
11869638 - Perazine for schizophrenia.
15266518 - Non-invasive positive pressure ventilation for treatment of respiratory failure due to ...
25214778 - Once-daily indacaterol 75 μg in moderate- to-severe copd: results of a phase iv study ...
3048118 - Clinical and psychobiological characteristics of simultaneous panic disorder and major ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2007-01-16
Journal Detail:
Title:  European heart journal     Volume:  28     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-02-16     Completed Date:  2007-11-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  469-77     Citation Subset:  IM    
Epidemiology Unit, Department of Cardiology, Paseo Vall d'Hebron Hospital, Barcelona 119-129, 08035, Spain, and Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / therapeutic use*
Arrhythmias, Cardiac / therapy*
Chemotherapy, Adjuvant
Clinical Trials as Topic
Defibrillators, Implantable*
Treatment Outcome
Reg. No./Substance:
0/Anti-Arrhythmia Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevalence and prognostic implications of non-sustained ventricular tachycardia in ST-segment elevat...
Next Document:  The common non-synonymous variant G38S of the KCNE1-(minK)-gene is not associated to QT interval in ...